Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Research & Development (2016 - 2025)

Historic Research & Development for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $34.1 million.

  • Rocket Pharmaceuticals' Research & Development fell 1948.95% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.0 million, marking a year-over-year decrease of 1457.94%. This contributed to the annual value of $171.2 million for FY2024, which is 810.23% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Research & Development stood at $34.1 million, which was down 1948.95% from $42.7 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Research & Development high stood at $51.4 million for Q2 2023, and its period low was $24.5 million during Q2 2021.
  • Moreover, its 5-year median value for Research & Development was $41.7 million (2023), whereas its average is $40.1 million.
  • Within the past 5 years, the most significant YoY rise in Rocket Pharmaceuticals' Research & Development was 8294.78% (2021), while the steepest drop was 3408.86% (2021).
  • Over the past 5 years, Rocket Pharmaceuticals' Research & Development (Quarter) stood at $33.0 million in 2021, then soared by 51.55% to $50.0 million in 2022, then decreased by 16.57% to $41.7 million in 2023, then dropped by 10.51% to $37.4 million in 2024, then dropped by 8.8% to $34.1 million in 2025.
  • Its Research & Development stands at $34.1 million for Q3 2025, versus $42.7 million for Q2 2025 and $35.9 million for Q1 2025.